Anscombe’s model for sequential clinical trials revisited
From MaRDI portal
Publication:4639224
DOI10.1080/07474946.2018.1427982zbMath1486.62283arXiv1712.05547OpenAlexW2964058159MaRDI QIDQ4639224
No author found.
Publication date: 3 May 2018
Published in: Sequential Analysis (Search for Journal in Brave)
Full work available at URL: https://arxiv.org/abs/1712.05547
Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian problems; characterization of Bayes procedures (62C10) Stopping times; optimal stopping problems; gambling theory (60G40) Sequential statistical analysis (62L10)
Related Items (1)
Cites Work
- Unnamed Item
- Unnamed Item
- Unnamed Item
- Unnamed Item
- Unnamed Item
- Optimal stopping for Brownian motion with applications to sequential analysis and option pricing
- On the Lambert \(w\) function
- Optimal stopping under ambiguity in continuous time
- Bayesian sequential testing of the drift of a Brownian motion
- On Chernoff's Hypotheses Testing Problem for the Drift of a Brownian Motion
- A harmonic function technique for the optimal stopping of diffusions
- Optimal Stopping With Multiple Priors
- Numerical Solutions for Bayes Sequential Decision Problems
- Truncated sequential medical trials involving paired data
- Sequential medical trials involving paired data
- Sequential analysis of comparative clinical trials
- The Inverse of the Cumulative Standard Normal Probability Function
- Determination of the optimal sample size for a clinical trial accounting for the population size
- Sequential Tests for the Mean of a Normal Distribution II (Large $t$)
- Sequential decisions in the control of a space-ship (finite fuel)
- Sequential Test for the Mean of a Normal Distribution III (Small $t$)
- Optimum Character of the Sequential Probability Ratio Test
- Business Failures: Another Example of the Analysis of Failure Data
- Sequential Tests of Statistical Hypotheses
- Stochastic differential equations. An introduction with applications.
This page was built for publication: Anscombe’s model for sequential clinical trials revisited